PEG-IFNα-2b辅助恩替卡韦治疗HBeAg阴性慢性乙肝的效果研究  

Study on the Effect of PEG-IFNα-2b Assisted Entecavir in the Treatment of HBeAg-negative Chronic Hepatitis B

作　　者：王春艳 许维国 WANG Chunyan;XU Weiguo(Tianjin Binhai New Area Tanggu Infectious Diseases Hospital,Tianjin 300450,China)

机构地区：[1]天津市滨海新区塘沽传染病医院,天津300450

出　　处：《中国药物滥用防治杂志》2024年第4期714-717,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探究对HBeAg阴性慢性乙肝患者给予恩替卡韦结合PEG-IFNα-2b的可行性及有效性,以为临床治疗方案提供参考依据。方法:选择2017年4月—2019年4月本院收治的HBeAg阴性慢性乙肝患者80例,根据治疗方法不同将其分成对照组45例和观察组35例。对照组予以恩替卡韦治疗,观察组在对照组基础上加用PEG-IFNα-2b联治。比较两组治疗前后肝功能指标、肝纤维化水平、生活质量及HBsAg清除率。结果:观察组总胆红素、间接胆红素、直接胆红素、谷丙转氨酶、天门冬氨酸氨基转移酶、甲胎蛋白、层黏蛋白、透明质酸、Ⅲ型前胶原水平低于对照组(P<0.05);观察组治疗后生理、症状、心理、社会等QLS-CHB评分均高于对照组(P<0.05);经随访后12个月,观察组HBsAg清除率为25.71%,高于对照组的2.22%(P<0.05)。结论:恩替卡韦结合PEG-IFNα-2b治疗HBeAg阴性慢性乙肝患者具有较好的应用效果,在改善患者肝功能指标、提升患者HBsAg清除率等方面有着积极影响。Objective:To explore the feasibility and efectiveness of entecavir combined with PEG-IFNα-2b in patients with HBeAgnegative chronic hepatitis B,so as to provide reference for clinical treatment.Methods:A total of 80 patients with HBeAg-negative chronic hepatitis B admitted to our hospital from April 2017 to April 2019 were selected and divided into control group(45 patients)and observation group(35 patients)according to diferent treatment methods.The control group was treated with entecavir,and the observation group was treated with PEG-IFNα-2 b on the basis of the control group.The liver function indexes,liver fbrosis level,quality of life and HBsAg clearance rate were compared between the two groups before and after treatment.Results:The levels of total bilirubin,indirect bilirubin,direct bilirubin,alanine aminotransferase,aspartate aminotransferase,alpha-fetoprotein,laminin,hyaluronic acid and typeⅢprocollagen in the observation group were lower than those in the control group(P<0.05).After treatment,the QLS-CHB scores of physiology,symptoms,psychology and society in the observation group were higher than those in the control group(P<0.05).After 12 months of follow-up,the HBsAg clearance rate in the observation group was 25.71%,which was higher than 2.22%in the control group(P<0.05).Conclusion:Entecavir combined with PEG-IFNα-2b has a good application efect in the treatment of HBeAg-negative chronic hepatitis B patients,and has a positive impact on improving the liver function index and HBsAg clearance rate of patients.

关 键 词：恩替卡韦 HBEAG阴性慢性乙肝 PEG-IFNα-2b HBsAg清除率 

分 类 号：R512.62[医药卫生—内科学]